Alan S Coates

Summary

Affiliation: International Breast Cancer Study Group
Country: Switzerland

Publications

  1. ncbi request reprint Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
    Alan S Coates
    International Breast Cancer Study Group IBCSG, IBCSG Coordinating Center, Bern, Switzerland
    J Clin Oncol 25:486-92. 2007
  2. doi request reprint Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
    Diana Crivellari
    IBCSG Coordinating Center, Effingerstrasse 40, CH 3008 Bern, Switzerland
    J Clin Oncol 26:1972-9. 2008
  3. ncbi request reprint Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
    Jurg Bernhard
    International Breast Cancer Study Group IBCSG, Bern, Switzerland
    J Clin Oncol 25:263-70. 2007
  4. ncbi request reprint Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
    Monica Castiglione-Gertsch
    International Breast Cancer Study Group Coordinating Center and Inselspital, Bern, Switzerland
    J Natl Cancer Inst 95:1833-46. 2003
  5. pmc Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
    Marco Colleoni
    Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy Zhuoxin Sun, Karen N Price, and Richard D Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation Zhuoxin Sun and Richard D Gelber, Harvard T F Chan School of Public Health Richard D Gelber, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden John F Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle Alan S Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland
    J Clin Oncol 34:927-35. 2016
  6. pmc Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 20:1319-29. 2009
  7. pmc Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 117:319-24. 2009
  8. pmc Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 116:491-500. 2009
  9. pmc Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
    Otto Metzger Filho
    Otto Metzger Filho, Anita Giobbie Hurder, and Eric P Winer, Dana Farber Cancer Institute Richard D Gelber and Meredith M Regan, Harvard Medical School Karen N Price, Frontier Science and Technology Research, Boston, MA Elizabeth Mallon, Southern General Hospital Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom Giuseppe Viale, European Institute of Oncology and University of Milan Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy Beat Thürlimann, Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark Marc Debled, Institut Bergoniié, Bordeaux, France and Alan S Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia
    J Clin Oncol 33:2772-9. 2015
  10. ncbi request reprint A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    R Charles Coombes
    Department of Cancer Medicine, Imperial College and Charing Cross Hospital, London, United Kingdom
    N Engl J Med 350:1081-92. 2004

Detail Information

Publications37

  1. ncbi request reprint Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
    Alan S Coates
    International Breast Cancer Study Group IBCSG, IBCSG Coordinating Center, Bern, Switzerland
    J Clin Oncol 25:486-92. 2007
    ..Because this presentation may unduly reflect early events, the present analysis is limited to patients randomly assigned to the continuous therapy arms and includes protocol-defined updated results...
  2. doi request reprint Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
    Diana Crivellari
    IBCSG Coordinating Center, Effingerstrasse 40, CH 3008 Bern, Switzerland
    J Clin Oncol 26:1972-9. 2008
    ..To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial...
  3. ncbi request reprint Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
    Jurg Bernhard
    International Breast Cancer Study Group IBCSG, Bern, Switzerland
    J Clin Oncol 25:263-70. 2007
    ....
  4. ncbi request reprint Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
    Monica Castiglione-Gertsch
    International Breast Cancer Study Group Coordinating Center and Inselspital, Bern, Switzerland
    J Natl Cancer Inst 95:1833-46. 2003
    ....
  5. pmc Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
    Marco Colleoni
    Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy Zhuoxin Sun, Karen N Price, and Richard D Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation Zhuoxin Sun and Richard D Gelber, Harvard T F Chan School of Public Health Richard D Gelber, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden John F Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle Alan S Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland
    J Clin Oncol 34:927-35. 2016
    ..We identified patient populations that remain at risk for an event at a median follow-up of 24 years from the diagnosis of operable breast cancer...
  6. pmc Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 20:1319-29. 2009
    ..The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm...
  7. pmc Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 117:319-24. 2009
    ..Despite small numbers of patients, "old-fashioned" treatments, and competing causes of treatment failure, the value of ER status as a target for response to adjuvant treatment is evident through prolonged follow-up...
  8. pmc Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 116:491-500. 2009
    ..03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high...
  9. pmc Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
    Otto Metzger Filho
    Otto Metzger Filho, Anita Giobbie Hurder, and Eric P Winer, Dana Farber Cancer Institute Richard D Gelber and Meredith M Regan, Harvard Medical School Karen N Price, Frontier Science and Technology Research, Boston, MA Elizabeth Mallon, Southern General Hospital Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom Giuseppe Viale, European Institute of Oncology and University of Milan Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy Beat Thürlimann, Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark Marc Debled, Institut Bergoniié, Bordeaux, France and Alan S Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia
    J Clin Oncol 33:2772-9. 2015
    ..To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients with invasive ductal or lobular carcinoma...
  10. ncbi request reprint A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    R Charles Coombes
    Department of Cancer Medicine, Imperial College and Charing Cross Hospital, London, United Kingdom
    N Engl J Med 350:1081-92. 2004
    ..Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse...
  11. ncbi request reprint Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group
    Lorenzo Gianni
    Divisione di Oncologia e di Ematologia, Ospedale degli Infermi, and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Azienda USL Rimini Via Settembrini 2, Rimini, Italy
    Support Care Cancer 16:67-74. 2008
    ..The objective of this study was to evaluate the incidence of anemia and risk factors for anemia occurrence in patients with early breast cancer who received adjuvant chemotherapy...
  12. ncbi request reprint Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 25:3846-52. 2007
    ..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer...
  13. ncbi request reprint Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
    Henning Mouridsen
    Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark
    J Clin Oncol 25:5715-22. 2007
    ..The purpose of the present study is to provide detailed updated information on these AEs in BIG 1-98...
  14. ncbi request reprint Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
    Birgitte B Rasmussen
    Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
    Lancet Oncol 9:23-8. 2008
    ..Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours...
  15. doi request reprint Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  16. ncbi request reprint Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from I
    Vito J Spataro
    Department of Medical Oncology, Ospedale San Giovanni, Bellinzona, Switzerland
    Cancer 97:1591-600. 2003
    ....
  17. doi request reprint Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:1404-10. 2008
    ....
  18. doi request reprint Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer
    Vlatka M Duric
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Patient Educ Couns 72:239-45. 2008
    ..Preferences of women who had completed adjuvant chemotherapy for early breast cancer were compared with those of their partners by determining the smallest benefits they judged sufficient to make adjuvant chemotherapy worthwhile...
  19. doi request reprint A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    Clin Breast Cancer 8:287-92. 2008
    ..Although multidrug regimens are preferred, the agents, doses, and use of supportive therapy are at the discretion of the investigator...
  20. ncbi request reprint Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:1177-84. 2007
    ..The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome...
  21. ncbi request reprint Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials
    Lorenzo Gianni
    Division of Oncology and Hematology, Hospital degli Infermi, Rimini, Italy
    Cancer 106:505-13. 2006
    ..Others have reported ocular toxicity after adjuvant chemoendocrine therapy, but this study looked at ocular toxicity in similarly treated patients from large randomized clinical trials...
  22. ncbi request reprint Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca
    Günther Gruber
    Department of Radiation Oncology, and the Institute of Medical Oncology, Inselspital, Switzerland
    J Clin Oncol 23:7089-97. 2005
    ..We sought to determine retrospectively whether extracapsular spread (ECS) might identify a subgroup that could benefit from radiotherapy after mastectomy, especially patients with 1 to 3 positive lymph nodes (LN1-3+)...
  23. ncbi request reprint Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93
    Carl Magnus Rudenstam
    West Swedish Breast Cancer Study Group, Sahlgrenska University Hospital Molndal, Göteborgsvägen 31, 431 80 Mölndal, Sweden
    J Clin Oncol 24:337-44. 2006
    ..We therefore investigated whether avoiding axillary surgery in older women would result in improved quality of life (QL) with similar disease-free survival (DFS) and overall survival (OS)...
  24. ncbi request reprint A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    Beat Thurlimann
    Senology Center of Eastern Switzerland, Kantonsspital, St Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland
    N Engl J Med 353:2747-57. 2005
    ..We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women...
  25. ncbi request reprint Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95
    Russell L Basser
    CSL Ltd, 45 Poplar Rd, Parkville, VIC 3052, Australia
    J Clin Oncol 24:370-8. 2006
    ....
  26. ncbi request reprint Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 24:1332-41. 2006
    ..The value of adjuvant tamoxifen after chemotherapy for premenopausal women with breast cancer has not been adequately assessed...
  27. ncbi request reprint Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer
    Vlatka M Duric
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
    Psychooncology 16:48-59. 2007
    ..We sought to better understand such preferences by assessing associations between preferences and psychosocial factors, and by asking women who judged negligible benefits sufficient to explain why...
  28. ncbi request reprint Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Natl Cancer Inst 98:1571-81. 2006
    ..ER-positive premenopausal patients required further study...
  29. ncbi request reprint Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV
    Diana Crivellari
    Centro di Riferimento Oncologico, Via Pedemontana Occidentale 12, I 33081 Aviano, Italy
    J Clin Oncol 21:4517-23. 2003
    ..The role of adjuvant therapy for this population is still a matter of debate. We reviewed the long-term outcome of a mature trial comparing endocrine treatment versus no adjuvant therapy in older women with node-positive breast cancer...
  30. ncbi request reprint Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93
    Olivia Pagani
    Instituto Oncologico Svizzera Italiana IOSI, Ospedale Beata Vergine, Mendrisio, Switzerland
    Ann Oncol 15:1749-59. 2004
    ..This is the first report of the endocrine comparison after a median follow-up of 5.5 years...
  31. ncbi request reprint Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
    Marco Colleoni
    European Institute of Oncology, Milan, Italy
    Lancet 366:1108-10. 2005
    ..44] for overall survival) [interaction p values=0.0001 for disease-free survival and 0.0019 for overall survival]. Our findings suggest that for women with ER-absent or ER-low tumours, reduction in chemotherapy dose should be avoided...
  32. ncbi request reprint Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1390-400. 2005
    ..For medial tumors, axillary lymph node staging may not accurately reflect the metastatic potential of the disease...
  33. ncbi request reprint Prediction of cancer outcome with microarrays
    Aron Goldhirsch
    Lancet 365:1685-6; author reply 1686. 2005
  34. doi request reprint Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
    Bernhard C Pestalozzi
    Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
    J Clin Oncol 26:3006-14. 2008
    ..To determine how patients with infiltrating lobular carcinoma (ILC) differ from patients with the more common infiltrating ductal carcinoma (IDC) with regard to patient and tumor factors, local treatment, and patterns of recurrence...
  35. ncbi request reprint The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
    Per Karlsson
    Department of Oncology, University of Goteborg, Sahlgrenska University Hospital, Goteborg, Sweden
    J Clin Oncol 25:2019-26. 2007
    ..To identify groups of early breast cancer patients with substantial risk (10-year risk > 20%) for locoregional failure (LRF) who might benefit from postmastectomy radiotherapy (RT)...
  36. ncbi request reprint Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
    Aron Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano
    J Clin Oncol 21:3357-65. 2003
    ....
  37. ncbi request reprint Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
    Helen Trihia
    International Breast Cancer Study Group Pathology Center, Western Infirmary, Glasgow, United Kingdom
    Cancer 97:1321-31. 2003
    ..The Ki-67 nuclear antigen may be considered as an alternative to mitotic counts in grading schemes and as a single parameter that can be used in fine-needle aspirates and small biopsies...